Dechra Pharm Plc (DPH.L)

Trade DPH.L now with
2/21/2022 2:06:55 AM Dechra HY Underlying EPS Growth Of 24.0% At CER To 64.01p; Interim Dividend Increased By 8.0% To 12.00p
1/13/2022 2:10:39 AM Dechra Pharma 6-month Group Net Revenue Up About 15% At Constant Exchange Rates
1/11/2022 2:01:52 AM Dechra Pharma Agrees Terms With Anivive Lifesciences To Buy Worldwide Rights To Verdinexor For Dogs
10/21/2021 2:07:55 AM Dechra Pharma Issues AGM Statement; Says Trading Is Currently Encouraging
9/6/2021 2:27:11 AM Dechra Pharm FY Revenue Up 21.0% To £608.0 Mln
7/12/2021 2:23:47 AM Dechra Pharma FY Reported Group Revenue Up About 21% At CER
6/8/2021 2:03:19 AM Dechra Pharma Now Expects FY Revenue To Be Ahead Of Current Consensus View
3/31/2021 4:05:08 AM Dechra Pharma Appoints Denise Goode As Non-Executive Director
2/22/2021 2:07:56 AM Dechra Pharma 6-month Underlying EPS 54.28p Vs 43.46p Last Year
2/8/2021 2:02:50 AM Dechra Pharma Secures Rights To Market Tri-Solfen In Australia And New Zealand
1/14/2021 2:11:06 AM Dechra Says Outlook For Full Financial Year Is Currently Ahead Of Management Expectations
12/15/2015 7:46:35 AM RBC Capital Markets Initiates Dechra Pharm PLC (DPH.L) At Sector Perform